
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington - A ceramide-dominant barrier repair moisturizer (TriCeram) is a valuable adjuvant in the treatment of atopic dermatitis, according to the results of a study presented by University of California, San Francisco dermatology researchers at the annual meeting of the Society for Investigative Dermatology.